{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
Vivant True Tone Forte by Vivant Pharmaceuticals, LLC
(2024)
Source URL:
First approved in 2024
Source:
Vivant True Tone Forte by Vivant Pharmaceuticals, LLC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M032
(2024)
Source URL:
First approved in 2024
Source:
M032
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class:
POLYMER
Surfomer (also known as alpha-olefin maleic acid) is a copolymer of maleic acid and alpha-olefin useful for control of whole-body cholesterol homeostasis. Surfomer reduces intestinal cholesterol absorption by decreasing membrane hydrophobicity at microvillus level thereby impairing the interaction with intestinal cholesterol of both exogenous and endogenous origin. In the hamsters, Surfomer was shown to effectively reduce intestinal cholesterol absorption in a dose-dependent manner, to increase hepatic and intestinal cholesterol synthesis and to decrease plasma total and LDL-cholesterol.
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
HYDROQUINONE 4% by Akron Pharma Inc
(2024)
Source URL:
First approved in 2024
Source:
HYDROQUINONE 4% by Akron Pharma Inc
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M015
(2024)
Source URL:
First approved in 2024
Source:
M015
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2024
Source:
M020
Source URL:
Class:
POLYMER